← Eichor
Study identifier: NCT06445972 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)

Condition: Gastroesophageal Junction · Gastroesophageal Adenocarcinoma · Esophageal Neoplasms  ·  Sponsor: Merck Sharp & Dohme LLC

PhasePhase 1/Phase 2
Planned participants210
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This is a phase 1/2 multicenter, open-label umbrella platform study that will evaluate the safety and efficacy of sacituzumab tirumotecan (MK-2870) plus paclitaxel versus ramucirumab plus paclitaxel, and HER3-DXD plus ramucirumab versus ramucirumab plus paclitaxel for the treatment of participants with advanced or metastatic gastric adenocarcinoma, gastroesophageal junction (GEJ) adenocarcinoma, or esophageal adenocarcinoma who have failed 1 prior line of therapy. This is an estimation study, and no formal hypothesis testing will be performed.

This description comes directly from the study's public registry record.

Talk to the study team

Toll Free Number  ·  1-888-577-8839  ·  Trialsites@msd.com

Always discuss trial participation with your own doctor first.

Locations (47)

University of Arizona Cancer Center-University of Arizona Cancer Center ( Site 8927)Tucson, Arizona, United StatesRecruiting
UCLA Hematology/Oncology - Santa Monica ( Site 8905)Los Angeles, California, United StatesRecruiting
Norton Cancer Institute - Downtown ( Site 8900)Louisville, Kentucky, United StatesCompleted
The Cancer and Hematology Centers ( Site 8912)Grand Rapids, Michigan, United StatesRecruiting
Hematology-Oncology Associates of Central NY, P.C. ( Site 8925)East Syracuse, New York, United StatesRecruiting
Columbia University Irving Medical Center-CUIMC Herbert Irving Comprehensive Cancer Center Clinical ( Site 8907)New York, New York, United StatesCompleted
UPMC Hillman Cancer Center-UPMC ( Site 8904)Pittsburgh, Pennsylvania, United StatesRecruiting
University of Texas MD Anderson Cancer Center ( Site 8920)Houston, Texas, United StatesRecruiting
Liga Norte Riograndense Contra o Câncer ( Site 8303)Natal, Rio Grande do Norte, BrazilRecruiting
Hospital Nossa Senhora da Conceição ( Site 8301)Porto Alegre, Rio Grande do Sul, BrazilRecruiting
IBCC - Instituto Brasileiro de Controle do Câncer ( Site 8304)São Paulo, São Paulo, BrazilRecruiting
ICESP - INSTITUTO DO CÂNCER DO ESTADO DE SÃO PAULO ( Site 8300)São Paulo, BrazilRecruiting

+ 35 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06445972